[It is anticipated that Sinovac's common shares will commence trading on NASDAQ on or about November 16, 2009. Sinovac will continue to trade under the ticker symbol "SVA." Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The transfer of our stock listing to NASDAQ demonstrates our continued focus on creating shareholder value. We appreciate the support that the] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

[I. SINOVAC REPORTS UNAUDITED SECOND QUARTER 2009 FINANCIAL RESULTS - Conference call scheduled Wednesday, August 19, 2009 at 8:00 a.m. ET - - Reaffirmation of 2009 sales projection to be $55 million to $60 million - - H1N1 vaccine may drive additional growth - BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

[Sinovac Reports Unaudited First Quarter 2009 Financial Results - Conference call scheduled Friday, May 15, 2009 at 9:00 a.m. ET- - Reaffirmation of 2009 sales projection to be $55 million to $60 million- BEIJING, May 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China has announced its unaudited financial results for] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

[Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea Clarifies Details of Agreement with Boryung BEIJING, Sept. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that it has signed an agreement with Boryung Pharmaceutical Company Limited, a Korean manufacturer of pharmaceuticals, to collaborate on marketing efforts] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

[Sinovac's H1N1 Vaccine Passes Experts Evaluation Organized by SFDA BEIJING, Aug. 31 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of biopharmaceutical products in China, announced today that Sinovac's H1N1 vaccine has passed the experts evaluation organized by State Food and Drug Administration (SFDA). The vaccine is expected to obtain the production license within this week. On] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]

[Sinovac Wins Beijing Public Health Bureau's Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine, for the] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]